Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done

Junnan TangNorth Carolina State University, College of Veterinary Medicine, Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, Raleigh, NC, USA;The First Affiliated Hospital of Zhengzhou University, Department of Cardiology, Zhengzhou, China

, PhD,

Deliang ShenThe First Affiliated Hospital of Zhengzhou University, Department of Cardiology, Zhengzhou, China

, PhD MD,

Jinying ZhangThe First Affiliated Hospital of Zhengzhou University, Department of Cardiology, Zhengzhou, China

, PhD MD,

Frances S LiglerUniversity of North Carolina at Chapel Hill and North Carolina State University, Department of Biomedical Engineering, 1060 William Moore Drive, Raleigh, NC 27607, USA+1 919 513 6157; +1 919 513 7301; [email protected]; [email protected]

, DPhil DSc &

Ke ChengNorth Carolina State University, College of Veterinary Medicine, Department of Molecular Biomedical Sciences and Center for Comparative Medicine and Translational Research, Raleigh, NC, USA;University of North Carolina at Chapel Hill and North Carolina State University, Department of Biomedical Engineering, 1060 William Moore Drive, Raleigh, NC 27607, USA+1 919 513 6157; +1 919 513 7301; [email protected]; [email protected];Soochow University, The Cyrus Tang Hematology Center, Suzhou, China

, PhD (Associate Professor of Regenerative Medicine)

Figures & data

Figure 1. (A) Bispecific T cell engager antibodies are designed to exclusively target T cells and transiently engage activated T-cells for lysis of selected cancerous cells. (B) Bispecific antibodies were armed with CD34⁺ stem cells prior to intravenous infusion. After infusion, armed CD34⁺ stem cells could target the injured myocardium, which expressed an injury biomarker MLC. (C) Anti-CD45 antibody was modified with Traut’s reagent and anti-MLC was modified with sulfosuccinimidyl 4-(N-maleimidomethyl) cyclohexane1-carboxylate (SulfoSMCC); mixture of the two and overnight crosslinking produced a BiAbs with anti-CD45 × anti-MLC specificities.

Figure 2. Magnetic bispecific cell engager agents are iron nanoparticles conjugated with two types of antibodies, one against antigens on therapeutic cells and the other directed at injured cells.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Bispecific antibodies, nanoparticles and cells: bringing the right cells to get the job done

Figures & data

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date